A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
Paula M. Fracasso(University of Virginia), Helen Piwnica‐Worms(Centre for Cancer Biology)
Cited by 69
Related Papers
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
Kinetics of regulated protein–protein interactions revealed with firefly luciferase complementation imaging in cells and living animals
|Proceedings of the National Academy of Sciences|2004|443
Contribution of p53 to Metastasis
|Cancer Discovery|2014|368
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
|Science Translational Medicine|2019|316